TrialThe journal of headache and pain2020

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.

Stephen Silberstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.